Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Novo Nordisk, Wegovy
Novo’s Wegovy Backed by EU Regulator For Obesity-Related Heart Conditions. FDA Could Be Next.
Novo Nordisk’s obesity drug Wegovy is now recommended by EU regulatory authorities for obesity-related heart conditions. Approval in the U.S.–Novo’s biggest market for obesity drugs–by the Food and Drug Administration could be next.
EMA CHMP recommends label update to Novo Nordisk’s Wegovy
Committee for Medicinal Products for Human Use (CHMP) has recommended an update to Novo Nordisk’s Wegovy (semaglutide 2.4 mg) label. This update in the European Union (EU) reflects new data indicating the product’s ability,
Wegovy® recommended by the European regulatory authorities for label update to reflect reduced heart failure symptoms and improved physical function
BAGSVAERD, Denmark I 19, 2024 I Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human
Novo Nordisk's Wegovy Recommended For Label Update To Reflect Heart Failure Benefits
Novo Nordisk said that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a
European Drug Agency Supports Novo Nordisk's Blockbuster Weight-Loss Drug Wegovy For Obesity-Related Heart Failure
Novo Nordisk's Wegovy label update receives a positive opinion from the EMA's CHMP, highlighting improvements in heart failure symptoms, physical limitations, and exercise function in patients with obesity-related HFpEF.
Wegovy label should be extended, CHMP recommends
The European Medicines Agency’s (EMA) advisory committee the CHMP has adopted a positive opinion for a label update of Danish drugmaker Novo Nordisk’s Wegovy (semaglutide 2.4mg).
Novo Nordisk’s Wegovy Gets EU Backing to Treat Obesity-Related Heart Failure
Novo Nordisk said European regulators support the use of its blockbuster weight-loss drug Wegovy to help reduce heart failure in obese patients.
Medscape
1h
Semaglutide Bests Liraglutide in Long-Term Weight Loss
Researchers found that patients with obesity had an average weight loss of 12.9% with semaglutide vs 5.6% with liraglutide ...
1d
on MSN
Hims & Hers offers compounded Wegovy for $99 a month to select professions
U.S. telehealth company Hims & Hers Health on Wednesday said it will sell compounded versions of Novo Nordisk's popular ...
10d
Wegovy, Ozempic may someday be available as monthly injection
A slow-release form of semaglutide could allow people who use Wegovy or Ozempic to get shots once a month, instead of the ...
STAT
1d
Pharmalittle: We’re reading about a rare-disease drug bill, compounded Wegovy, and more
For patients on a 12-month plan, Hims offers a
semaglutide
injection for $199 a month. Ozempic and
Wegovy
carry high list prices of $935.77 and $1,349.02, respectively, for a month’s supply, ...
Everyday Health
6d
Wegovy May Reduce the Risk of Death From COVID-19, Study Suggests
A new study found that people taking Wegovy during the pandemic were 33 percent less likely to die of COVID-19.
7d
Experimental Weight Loss Drug Beat Ozempic and Wegovy in Early Trial
People taking the experimental drug amycretin were found to lose almost twice as much weight over a 12-week period as the ...
Knowridge
5d
Is Wegovy really a gamechanger for heart health? A consultant cardiologist gives his verdict
The weight-loss jab Wegovy has been hailed as an “absolute game-changer” after a new study showed that it relieved symptoms ...
4h
Explainer: The side-effects of Ozempic and Wegovy
Is it safe and what are the real risks beyond loose skin and “Ozempic face” – the gaunt ageing effect of drastic weight loss?
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Novo Nordisk
European Union
Ozempic
Feedback